Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The trial is a double-blinded randomized study that will examine whether switching to a
selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi
(golimumab) among patients with PsA who have an inadequate response to a TNFi.